This HTML5 document contains 117 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n25http://linked.opendata.cz/resource/AHFS/
n21http://linked.opendata.cz/resource/drugbank/drug/DB01140/identifier/national-drug-code-directory/
foafhttp://xmlns.com/foaf/0.1/
n27http://linked.opendata.cz/resource/mesh/concept/
n4http://linked.opendata.cz/resource/drugbank/company/
n9http://linked.opendata.cz/resource/drugbank/dosage/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01140/identifier/chebi/
n12http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n24http://www.rxlist.com/cgi/generic/
n23http://linked.opendata.cz/resource/drugbank/drug/DB01140/identifier/wikipedia/
n22http://linked.opendata.cz/resource/drugbank/drug/DB01140/identifier/pharmgkb/
n15http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n18http://linked.opendata.cz/resource/drugbank/drug/DB01140/identifier/kegg-compound/
n8http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n26http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n17http://www.drugs.com/cdi/
n5http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/resource/drugbank/drug/DB01140/identifier/kegg-drug/
n7http://linked.opendata.cz/resource/atc/
n20http://linked.opendata.cz/resource/drugbank/drug/DB01140/identifier/drugbank/
n6http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01140
rdf:type
n3:Drug
n3:description
Long-acting, broad-spectrum, water-soluble, cephalexin derivative. [PubChem]
n3:dosage
n9:271B47CE-363D-11E5-9242-09173F13E4C5 n9:271B47CF-363D-11E5-9242-09173F13E4C5 n9:271B47D0-363D-11E5-9242-09173F13E4C5 n9:271B47D1-363D-11E5-9242-09173F13E4C5 n9:271B47CC-363D-11E5-9242-09173F13E4C5 n9:271B47CD-363D-11E5-9242-09173F13E4C5
n3:group
approved withdrawn
n3:halfLife
1.5 hours
n3:indication
For the treatment of the following infections (skin, UTI, ENT) caused by; <i>S. pneumoniae, H. influenzae, staphylococci, S. pyogenes</i> (group A beta-hemolytic streptococci), <i>E. coli, P. mirabilis, Klebsiella</i> sp, coagulase-negative staphylococci and <i>Streptococcus pyogenes</i>
owl:sameAs
n12:DB01140 n15:DB01140
dcterms:title
Cefadroxil
adms:identifier
n14:3479 n18:C06878 n19:D00257 n20:DB01140 n21:0781-2938-50 n22:PA448835 n23:Cefadroxil
n3:mechanismOfAction
Like all beta-lactam antibiotics, cefadroxil binds to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, causing the inhibition of the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cefadroxil interferes with an autolysin inhibitor.
n3:packager
n4:271B47B5-363D-11E5-9242-09173F13E4C5 n4:271B47AA-363D-11E5-9242-09173F13E4C5 n4:271B47A6-363D-11E5-9242-09173F13E4C5 n4:271B47A7-363D-11E5-9242-09173F13E4C5 n4:271B47B2-363D-11E5-9242-09173F13E4C5 n4:271B47A4-363D-11E5-9242-09173F13E4C5 n4:271B47B3-363D-11E5-9242-09173F13E4C5 n4:271B47B0-363D-11E5-9242-09173F13E4C5 n4:271B47A5-363D-11E5-9242-09173F13E4C5 n4:271B47B1-363D-11E5-9242-09173F13E4C5 n4:271B47AE-363D-11E5-9242-09173F13E4C5 n4:271B47A3-363D-11E5-9242-09173F13E4C5 n4:271B47AF-363D-11E5-9242-09173F13E4C5 n4:271B47AD-363D-11E5-9242-09173F13E4C5 n4:271B47C7-363D-11E5-9242-09173F13E4C5 n4:271B47C9-363D-11E5-9242-09173F13E4C5 n4:271B47C5-363D-11E5-9242-09173F13E4C5 n4:271B47C6-363D-11E5-9242-09173F13E4C5 n4:271B47C8-363D-11E5-9242-09173F13E4C5 n4:271B47BB-363D-11E5-9242-09173F13E4C5 n4:271B47BC-363D-11E5-9242-09173F13E4C5 n4:271B47B9-363D-11E5-9242-09173F13E4C5 n4:271B47BA-363D-11E5-9242-09173F13E4C5 n4:271B47B7-363D-11E5-9242-09173F13E4C5 n4:271B47B8-363D-11E5-9242-09173F13E4C5 n4:271B47A8-363D-11E5-9242-09173F13E4C5 n4:271B47A9-363D-11E5-9242-09173F13E4C5 n4:271B47C3-363D-11E5-9242-09173F13E4C5 n4:271B47C4-363D-11E5-9242-09173F13E4C5 n4:271B47C1-363D-11E5-9242-09173F13E4C5 n4:271B47C2-363D-11E5-9242-09173F13E4C5 n4:271B47BF-363D-11E5-9242-09173F13E4C5 n4:271B47C0-363D-11E5-9242-09173F13E4C5 n4:271B47B6-363D-11E5-9242-09173F13E4C5 n4:271B47AB-363D-11E5-9242-09173F13E4C5 n4:271B47BD-363D-11E5-9242-09173F13E4C5 n4:271B47BE-363D-11E5-9242-09173F13E4C5 n4:271B47AC-363D-11E5-9242-09173F13E4C5 n4:271B47B4-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Over 90% of the drug is excreted unchanged in the urine within 24 hours. It crosses the placenta and appears in breast milk.
n3:synonym
Cefadroxil Cephadroxil CDX Cefadroxil monohydrate Cefadroxil anhydrous Cefadroxilum D-Cefadroxil Cefadroxilo (6R,7R)-7-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
n3:toxicity
Nausea, vomiting, diarrhoea, allergic rashes may occur
n6:hasAHFSCode
n25:08-12-06-04
n3:foodInteraction
Food may reduce the digestive problems that sometimes occur. Take without regard to meals.
n3:proteinBinding
Binding rates of cefadroxil were 28.1% by U.F. method
n3:synthesisReference
Leonardo Marsili, "Substantially anhydrous crystalline cefadroxil and method for producing it." U.S. Patent US5329001, issued April, 1978.
n26:hasConcept
n27:M0003714
foaf:page
n17:cefadroxil.html n24:cefadrox.htm
n3:IUPAC-Name
n5:271B47D6-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B47DC-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B47DB-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B47D8-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B47D9-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B47DA-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B47D4-363D-11E5-9242-09173F13E4C5 n5:271B47EC-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B47D2-363D-11E5-9242-09173F13E4C5 n5:271B47D5-363D-11E5-9242-09173F13E4C5 n5:271B47EE-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B47D3-363D-11E5-9242-09173F13E4C5
n6:hasATCCode
n7:J01DB05
n3:H-Bond-Acceptor-Count
n5:271B47E2-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B47E3-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B47DD-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B47DE-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B47E0-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B47DF-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B47E1-363D-11E5-9242-09173F13E4C5
n3:absorption
Cefadroxil is well absorbed on oral administration; food does not interfere with its absorption.
n3:affectedOrganism
Enteric bacteria and other eubacteria
n3:casRegistryNumber
66592-87-8
n3:category
n3:containedIn
n8:271B47CA-363D-11E5-9242-09173F13E4C5 n8:271B47CB-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B47E8-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B47EA-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B47EB-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n5:271B47ED-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B47E7-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B47E6-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B47E9-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B47D7-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B47E4-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B47E5-363D-11E5-9242-09173F13E4C5